Comprehensive Tumor Panel (SNVs, InDels, CNVs & Fusions) + TMB + MSI near me in Hyderabad

MedGenome's Comprehensive Tumor Panel (SNVs, InDels, CNVs & Fusions) + TMB + MSI is a cutting-edge, high-throughput next-generation sequencing assay designed to unearth critical genomic aberrations responsible for cancer development. This comprehensive panel goes beyond conventional testing, as it encompasses a wide range of alterations, including single nucleotide variants (SNVs), insertions and deletions (InDels), copy number variations (CNVs), gene fusions, as well as measures of tumor mutation burden (TMB) and microsatellite instability (MSI). By doing so, it equips oncologists with a holistic view of a patient's tumor, facilitating tailored treatment strategies.

The panel comprises a multitude of cancer-related genes of over 324 genes, aligning with the NCCN guidelines, and exhaustively reports both known and novel fusion gene partners. Furthermore, genes implicated in the Homologous Recombination Repair (HRR) pathway are included, offering a comprehensive assessment of potential therapeutic targets.

The TMB assessment is a standout feature, quantifying non-synonymous somatic variants normalized to the entire exome, providing a nuanced perspective of genomic instability. This hybrid capture assay leverages unique molecular barcoding for precise tumor profiling.

In tandem, the Microsatellite Instability Assay scrutinizes DNA samples for MSI using multiplex PCR and fragment analysis across 13 mononucleotide markers, in accordance with NCI guidelines.

MedGenome's Comprehensive Tumor Panel offers a comprehensive genetic roadmap for oncologists, enabling tailored therapeutic decisions based on a thorough understanding of a patient's tumor biology.

Disclaimer: In no event shall the liability of TATA 1MG exceed the amount of actual cost of test charges incurred by the customer as stated on the invoice issued by Tata 1mg.